BMY: BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Pumitamig Data in Advanced NSCLC
Confirmed — Bristol Myers Squibb (BMY) and BioNTech published Phase 2 results for pumitamig in advanced non–small cell lung cancer (after progression on immunotherapy plus chemotherapy), reporting efficacy readouts and a manageable safety profile; BMY is showing confirmed news flow and elevated after‑hours activity in SMC data.